Allogene Therapeutics ALLO Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's total current liabilities?
- Allogene Therapeutics (ALLO) reported total current liabilities of $28.33M in Q1 2026.
- How has Allogene Therapeutics's total current liabilities changed year-over-year?
- Allogene Therapeutics's total current liabilities decreased by 5.6% year-over-year, from $30.02M to $28.33M.
- What is the long-term trend for Allogene Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Allogene Therapeutics's total current liabilities has grown at a -19.2% compound annual growth rate (CAGR), from $94.32M to $32.51M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.